TY - JOUR
T1 - After the pandemic
T2 - perspectives on the future trajectory of COVID-19
AU - Telenti, Amalio
AU - Arvin, Ann
AU - Corey, Lawrence
AU - Corti, Davide
AU - Diamond, Michael S.
AU - García-Sastre, Adolfo
AU - Garry, Robert F.
AU - Holmes, Edward C.
AU - Pang, Phillip S.
AU - Virgin, Herbert W.
N1 - Funding Information:
Competing interests A.T., A.A., D.C., P.P. and H.W.V. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. L.C., M.S.D. and E.C.H. are co-founders or consultants of Vir Biotechnology Inc. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna and Vir Biotechnology. The García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences and 7Hills Pharma. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Accurius and Esperovax. R.F.G. is co-founder of Zalgen Labs, a biotechnology company that develops countermeasures to emerging viruses.
Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2021/8/26
Y1 - 2021/8/26
N2 - There is a realistic expectation that the global effort in vaccination will bring the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control. Nonetheless, uncertainties remain about the type of long-term association that the virus will establish with the human population and, in particular, whether coronavirus disease 2019 (COVID-19) will become an endemic disease. Although the trajectory is difficult to predict, the conditions, concepts and variables that influence this transition can be anticipated. Persistence of SARS-CoV-2 as an endemic virus, perhaps with seasonal epidemic peaks, may be fuelled by pockets of susceptible individuals and waning immunity after infection or vaccination, changes in the virus through antigenic drift that diminish protection and re-entries from zoonotic reservoirs. Here we review relevant observations from previous epidemics and discuss the potential evolution of SARS-CoV-2 as it adapts during persistent transmission in the presence of a level of population immunity. Lack of effective surveillance or adequate response could enable the emergence of new epidemic or pandemic patterns from an endemic infection of SARS-CoV-2. There are key pieces of data that are urgently needed in order to make good decisions; we outline these and propose a way forward.
AB - There is a realistic expectation that the global effort in vaccination will bring the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control. Nonetheless, uncertainties remain about the type of long-term association that the virus will establish with the human population and, in particular, whether coronavirus disease 2019 (COVID-19) will become an endemic disease. Although the trajectory is difficult to predict, the conditions, concepts and variables that influence this transition can be anticipated. Persistence of SARS-CoV-2 as an endemic virus, perhaps with seasonal epidemic peaks, may be fuelled by pockets of susceptible individuals and waning immunity after infection or vaccination, changes in the virus through antigenic drift that diminish protection and re-entries from zoonotic reservoirs. Here we review relevant observations from previous epidemics and discuss the potential evolution of SARS-CoV-2 as it adapts during persistent transmission in the presence of a level of population immunity. Lack of effective surveillance or adequate response could enable the emergence of new epidemic or pandemic patterns from an endemic infection of SARS-CoV-2. There are key pieces of data that are urgently needed in order to make good decisions; we outline these and propose a way forward.
UR - http://www.scopus.com/inward/record.url?scp=85109797380&partnerID=8YFLogxK
U2 - 10.1038/s41586-021-03792-w
DO - 10.1038/s41586-021-03792-w
M3 - Review article
C2 - 34237771
AN - SCOPUS:85109797380
SN - 0028-0836
VL - 596
SP - 495
EP - 504
JO - Nature
JF - Nature
IS - 7873
ER -